Inhibition of hyperprogressive cancer disease induced by immune-checkpoint blockade upon co-treatment with meta-tyrosine and p38 pathway inhibitor

BACKGROUND: Although immune-checkpoint inhibitors (ICI) are overall promissory for cancer treatment, they entail, in some cases, an undesired side-effect called hyperprogressive-cancer disease (HPD) associated with acceleration of tumor growth and shortened survival. METHODS: To understand the mecha...

Descripción completa

Detalles Bibliográficos
Autores principales: Montagna, Daniela R., Duarte, Alejandra, Chiarella, Paula, Rearte, Bárbara, Bustuoabad, Oscar D., Vermeulen, Mónica, Ruggiero, Raúl A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347122/
https://www.ncbi.nlm.nih.gov/pubmed/35922755
http://dx.doi.org/10.1186/s12885-022-09941-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347122/
https://www.ncbi.nlm.nih.gov/pubmed/35922755
http://dx.doi.org/10.1186/s12885-022-09941-2

Ejemplares similares